Treatment of proton pump inhibitor-resistant patients with gastroesophageal reflux disease

J Gastroenterol. 2006 Mar;41(3):286-7. doi: 10.1007/s00535-006-1756-z.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Animals
  • Chemokine CXCL1
  • Chemokines, CXC / biosynthesis
  • Cyclooxygenase 2 / biosynthesis
  • Cyclooxygenase 2 / drug effects
  • Duodenogastric Reflux / complications
  • Duodenogastric Reflux / drug therapy*
  • Duodenogastric Reflux / enzymology*
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use*
  • Esophagitis / drug therapy*
  • Esophagitis / enzymology*
  • Esophagitis / etiology
  • Humans
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / metabolism
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • Nitric Oxide Synthase Type II / biosynthesis
  • Nitric Oxide Synthase Type II / drug effects
  • Proton Pump Inhibitors*
  • Proton Pumps / pharmacology
  • Proton Pumps / therapeutic use
  • RNA, Messenger / drug effects
  • RNA, Messenger / metabolism
  • Receptor, PAR-1 / biosynthesis
  • Receptor, PAR-1 / drug effects
  • Receptor, PAR-2 / biosynthesis
  • Receptor, PAR-2 / drug effects
  • Trypsin / drug effects*
  • Trypsin / metabolism

Substances

  • Chemokine CXCL1
  • Chemokines, CXC
  • Cxcl1 protein, rat
  • Enzyme Inhibitors
  • Proton Pump Inhibitors
  • Proton Pumps
  • RNA, Messenger
  • Receptor, PAR-1
  • Receptor, PAR-2
  • trypsin, pancreatic, type V-S
  • Nitric Oxide Synthase Type II
  • Cyclooxygenase 2
  • Trypsin